Clinical trials: Radiographic Contrast Agent Nephropathy
Chronic Kidney Disease
DyeVert™ Plus Contrast Reduction System Multicenter Observational Study
This is a prospective, single arm, multi-center, observational clinical study of the DyeVert Plus System. The DyeVert Plus System is an FDA-cleared device designed to reduce contrast media volume delivered during angiography and…
- Trial name
- NCT03715452
- Testing
- DyeVert Plus Contrast Reduction System
- Where
- 8 sites in United States
- Volunteers
- 114 people
- Sponsor
- Osprey Medical, Inc
Contrast-induced Nephropathy, Coronary Angiography
Relative Bioavailability of CE-Iohexol (Captisol-enabled™ Iohexol) Injection and Omnipaque™ Injection
This study is designed to compare the bioavailability of the test Product(CE-Iohexol Injection) and the reference product Iohexol Injection (Omnipaque™) following intravenous injection in normal healthy volunteers.
- Trial name
- NCT03869983
- Testing
- Omnipaque™ (iohexol) Injection, CE-Iohexol
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- CyDex Pharmaceuticals, Inc.
Radiographic Contrast Agent Nephropathy
Contrast Media Reduction and Removal in Patients With Chronic Kidney Disease (CKD) (PRESERV)
The purpose of this clinical trial is to demonstrate the efficacy and safety of the Osprey Medical CINCOR™ Contrast Removal System.
- Trial name
- NCT01168024
- Testing
- CINCOR™ System and contrast conservation unit (CCS-1), Standard of Care plus peri-procedural hydration
- Where
- 21 sites in United States, Germany
- Volunteers
- 16 people
- Sponsor
- Osprey Medical, Inc